Cholangiocyte Biology in Liver Diseases

Cholangiocytes, the specialised epithelial cells lining the intrahepatic and extrahepatic bile ducts, play a central role in bile secretion, modification and transport. Under physiological conditions, these cells maintain bile homeostasis through regulated ion and water transport and contribute to the liver’s barrier function. In the setting of liver injury, cholangiocytes undergo phenotypic changes characterised by proliferation, senescence or apoptosis, often accompanied by a ductular reaction that drives periductal inflammation and fibrogenesis. Through the release of cytokines, growth factors and extracellular vesicles, reactive cholangiocytes engage in bidirectional communication with hepatic stellate cells, immune cells and hepatocytes, thereby orchestrating tissue remodelling and scar formation. Dysregulated cholangiocyte signalling underlies the pathogenesis of cholangiopathies such as primary sclerosing cholangitis, primary biliary cholangitis and cholestatic drug-induced injury. Mechanistic studies have identified key mediators—such as the secretin/secretin receptor axis, YAP-mediated mechanotransduction, microRNA-200c control of IL-6/AKT feedback and PANoptosis associated with type-I interferon responses—as drivers of cholestasis and fibrosis. A deeper understanding of cholangiocyte biology offers routes to novel therapies, including small-molecule inhibitors, neutralising antibodies and natural product–derived agents that target fibrogenic and inflammatory circuits.

Research from Nature Portfolio

Recent studies have elucidated how the secretin/secretin receptor axis regulates cholangiocyte-to-cholangiocyte communication via extracellular vesicles. Bacterial lipopolysaccharide stimulation increases secretin-dependent release of vesicles from large cholangiocytes, which in turn induce proinflammatory cytokine production and proliferative responses in neighbouring ductal cells. Knockdown of either secretin or its receptor diminishes vesicle secretion and blunts downstream inflammatory signalling, highlighting a paracrine mechanism that contributes to biliary hyperplasia and inflammation.

Cholangiocyte Biology in Liver Diseases publication trend

The graph below shows the total number of articles in cholangiocyte biology in liver diseases across all publications each year (not limited to Nature Index journals).

Technical terms

Cholangiocyte: Epithelial cell lining the bile ducts, responsible for bile modification and transport.

Ductular reaction: Proliferation of bile ductules and associated stromal expansion in response to liver injury.

Extracellular vesicle (EV): Membrane-bound particle released by cells that carries proteins, lipids and nucleic acids for intercellular communication.

Cholestasis: Impaired bile flow leading to intrahepatic accumulation of bile acids and subsequent liver damage.

Fibrogenesis: Process of extracellular matrix deposition and scar formation driven by activated stellate cells and myofibroblasts.

Epithelial–mesenchymal transition (EMT): Phenotypic conversion of epithelial cells into motile, matrix-producing cells contributing to fibrosis.

PANoptosis: Integrated cell-death pathway combining pyroptosis, apoptosis and necroptosis often triggered by inflammatory signals.

References

1. The inhibition of YAP Signaling Prevents Chronic Biliary Fibrosis in the Abcb4-/- Model by Modulation of Hepatic Stellate Cell and Bile Duct Epithelium Cell Pathophysiology. Aging and Disease (2024).
2. Transcriptotype-Driven Discovery of Apigenin as a Therapy against Cholestatic Liver Fibrosis: Through Inhibition of PANoptosis and Following Type-I Interferon Responses. Antioxidants (2024).
3. CCL24 regulates biliary inflammation and fibrosis in primary sclerosing cholangitis. JCI Insight (2023).
4. The role of the secretin/secretin receptor axis in inflammatory cholangiocyte communication via extracellular vesicles. Scientific Reports (2017).
5. MiR-200c-3p targets SESN1 and represses the IL-6/AKT loop to prevent cholangiocyte activation and cholestatic liver fibrosis. Laboratory Investigation (2021).